< Back to search trials

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

  • Clinicaltrials.gov #: NCT03330847
  • Acronym: VIOLETTE
  • Tumor Type: Breast
  • Tumor Subtype: Triple Negatives
  • Tumor Stage: N/A
  • Type of Treatment: